$2.02
0.98% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

AbCellera Biologics Inc Stock price

$2.02
-0.59 22.61% 1M
-1.01 33.33% 6M
-0.91 31.06% YTD
-2.02 50.00% 1Y
-5.88 74.43% 3Y
-17.98 89.90% 5Y
-17.98 89.90% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.02 0.98%
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

Key metrics

Market capitalization $602.94m
Enterprise Value $-2.33m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
EV/Sales (TTM) EV/Sales -0.10
P/S ratio (TTM) P/S ratio 26.08
P/B ratio (TTM) P/B ratio 0.59
Revenue growth (TTM) Revenue growth -35.47%
Revenue (TTM) Revenue $23.12m
EBIT (operating result TTM) EBIT $-322.53m
Free Cash Flow (TTM) Free Cash Flow $-143.29m
Cash position $605.27m
EPS (TTM) EPS $-0.57
P/E forward negative
P/S forward 23.13
EV/Sales forward negative
Short interest 9.79%
Show more

Is AbCellera Biologics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

AbCellera Biologics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a AbCellera Biologics Inc forecast:

Buy
89%
Hold
11%

Financial data from AbCellera Biologics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
23 23
35% 35%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 84 84
9% 9%
363%
- Research and Development Expense 170 170
5% 5%
737%
-231 -231
14% 14%
-1,000%
- Depreciation and Amortization 91 91
286% 286%
395%
EBIT (Operating Income) EBIT -323 -323
42% 42%
-1,395%
Net Profit -168 -168
14% 14%
-726%

In millions USD.

Don't miss a Thing! We will send you all news about AbCellera Biologics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbCellera Biologics Inc Stock News

Neutral
Business Wire
2 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
Neutral
Business Wire
18 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.
Neutral
Business Wire
20 days ago
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit.
More AbCellera Biologics Inc News

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Carl Hansen
Employees 586
Founded 2012
Website www.abcellera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today